Pyxis Oncology Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Pyxis Oncology filed its Q1 2024 10-Q, detailing financial performance and ongoing licensing agreements.</b>

AI Summary

Pyxis Oncology, Inc. (PYXS) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Pyxis Oncology, Inc. filed a 10-Q for the period ending March 31, 2024. The filing details financial activities and business updates for Q1 2024. Key agreements mentioned include those with Pfizer, Novartis, Biosion, Mabwell, Simcere, and Toray. The company's fiscal year ends on December 31st. The filing references various stock and warrant activities, including an At-The-Market Offering Program.

Why It Matters

For investors and stakeholders tracking Pyxis Oncology, Inc., this filing contains several important signals. The 10-Q provides a quarterly update on Pyxis Oncology's financial health and operational progress, crucial for investors to assess the company's trajectory. Details on licensing agreements with major pharmaceutical partners like Pfizer and Novartis offer insights into potential future revenue streams and R&D collaborations.

Risk Assessment

Risk Level: — Pyxis Oncology, Inc. shows moderate risk based on this filing. The company's financial performance and cash burn rate, typical for development-stage biotechs, present a medium-term risk.

Analyst Insight

Monitor cash burn and progress on key licensing agreements for future funding and development milestones.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-14 — Filing Date (10-Q filing)
• 1231 — Fiscal Year End (Company data)

Key Players & Entities

• Pyxis Oncology, Inc. (company) — Filer name
• 2024-03-31 (date) — Period of report
• 2024-05-14 (date) — Filed as of date
• Pfizer (company) — Licensing agreement partner
• Novartis (company) — Licensing agreement partner
• Biosion (company) — Licensing agreement partner
• Mabwell (company) — Licensing agreement partner
• Simcere (company) — Licensing agreement partner

FAQ

Industry Context

Pyxis Oncology operates in the pharmaceutical preparations industry, focusing on the development of oncology therapeutics.

Regulatory Implications

The company is subject to standard SEC regulations for public filings, including the requirement to submit quarterly reports (10-Q).

What Investors Should Do

1. Review the detailed financial statements for Q1 2024 to understand revenue, expenses, and cash flow.
2. Analyze the status and terms of the various licensing and settlement agreements mentioned.
3. Assess the company's cash position and burn rate in the context of its development pipeline.

Year-Over-Year Comparison

This is the 10-Q filing for the first quarter of 2024, providing an update from previous filings.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share PYXS Nasdaq Global Select

Filing Documents

• pyxs-20240331.htm (10-Q) — 1731KB
• pyxs-ex31_1.htm (EX-31.1) — 14KB
• pyxs-ex31_2.htm (EX-31.2) — 14KB
• pyxs-ex32_1.htm (EX-32.1) — 8KB
• pyxs-ex32_2.htm (EX-32.2) — 8KB
• img32419210_0.jpg (GRAPHIC) — 74KB
• 0000950170-24-059099.txt (&nbsp;) — 6900KB
• pyxs-20240331.xsd (EX-101.SCH) — 1326KB
• pyxs-20240331_htm.xml (XML) — 768KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2024 and 2023 4 Condensed Consolidated Statements of Stockholders' Equity for the Three Months ended March 31, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24 PART II. OTHER INFORMATION 25 Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 77 Item 3. Defaults Upon Senior Securities 77 Item 4. Mine Safety Disclosures 77 Item 5. Other Information 77 Item 6. Exhibits 78

Signatures

Signatures 79 i SUMMA RY RISK FACTORS You should consider carefully the risks described under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q. References to "Pyxis Oncology," the "Company," "we," "us," and "our" in this section titled "Summary Risk Factors" refer to Pyxis Oncology, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: We are a clinical stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. We will require substantial additional capital to finance our operations, obtain regulatory approval for our product candidates, and commercialize our product candidates. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts. We are heavily dependent on the success of PYX-201, PYX-106 and PYX-107, which are in the early stages of development, and if PYX-201, PYX-106 and/or PYX-107 are not successful in clinical trials or do not receive regulatory approval or licensure or are not successfully commercialized, our business will be materially and adversely affected. Our product candidates may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory approval or licensure for or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. Our preclinical studies and clinical trials may fail to demonstrate adequately the s

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PYXIS ONCOLO GY, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 27,967 $ 9,664 Marketable debt securities, short-term 129,060 109,634 Restricted cash 1,472 1,472 Accounts receivable 8,000 — Prepaid expenses and other current assets 5,880 3,834 Total current assets 172,379 124,604 Property and equipment, net 11,333 11,872 Intangible assets, net 23,730 24,308 Operating lease right-of-use assets 12,778 12,942 Total assets $ 220,220 $ 173,726 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,293 $ 3,896 Accrued expenses and other current liabilities 10,828 12,971 Operating lease liabilities, current portion 1,020 1,232 Deferred revenues — 7,660 Total current liabilities 14,141 25,759 Operating lease liabilities, net of current portion 19,759 20,099 Deferred tax liability, net 2,164 2,164 Total liabilities 36,064 48,022 Commitments and contingencies (Note 14) Stockholders' equity: Preferred stock, par value $ 0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding — — Common stock, $ 0.001 par value per share; 190,000,000 shares authorized; 58,803,126 and 44,754,853 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. 59 45 Additional paid-in capital 473,638 411,821 Accumulated other comprehensive (loss) income ( 60 ) 63 Accumulated deficit ( 289,481 ) ( 286,225 ) Total stockholders' equity 184,156 125,704 Total liabilities and stockholders' equity $ 220,220 $ 173,726 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 PYXIS ONCOLOGY, INC. Condensed Consol